Insider Selling: Boston Scientific Co. (BSX) SVP Sells $107,727.48 in Stock
Boston Scientific Co. (NYSE:BSX) SVP Maulik Nanavaty sold 3,038 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $35.46, for a total value of $107,727.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Maulik Nanavaty also recently made the following trade(s):
- On Friday, November 16th, Maulik Nanavaty sold 23,458 shares of Boston Scientific stock. The shares were sold at an average price of $37.28, for a total value of $874,514.24.
Shares of BSX opened at $37.69 on Friday. Boston Scientific Co. has a 12-month low of $25.04 and a 12-month high of $39.44. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $50.94 billion, a P/E ratio of 29.91, a PEG ratio of 2.14 and a beta of 0.72.
A number of equities analysts have issued reports on the company. Argus increased their price target on Boston Scientific from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Friday, October 26th. Guggenheim increased their price target on Boston Scientific to $45.00 and gave the stock a “buy” rating in a report on Friday, November 16th. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, December 31st. Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Tuesday, January 8th. Finally, Barclays assumed coverage on Boston Scientific in a report on Monday, October 15th. They set an “overweight” rating and a $43.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $40.12.
Institutional investors and hedge funds have recently modified their holdings of the stock. Ipswich Investment Management Co. Inc. purchased a new stake in Boston Scientific in the 4th quarter valued at $28,000. West Oak Capital LLC raised its position in Boston Scientific by 40.0% in the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 300 shares during the last quarter. North Star Investment Management Corp. raised its position in Boston Scientific by 111.1% in the 4th quarter. North Star Investment Management Corp. now owns 2,280 shares of the medical equipment provider’s stock valued at $81,000 after buying an additional 1,200 shares during the last quarter. Moody National Bank Trust Division purchased a new stake in Boston Scientific in the 3rd quarter valued at $108,000. Finally, Capital Guardian Trust Co. purchased a new stake in Boston Scientific in the 3rd quarter valued at $110,000. Institutional investors own 90.71% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
See Also: Balanced Fund
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.